We are live on ! Find out more
TVTX icon

Travere Therapeutics
TVTX

126 hedge funds and large institutions have $875M invested in Travere Therapeutics in 2016 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 36 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

406% more call options, than puts

Call options by funds: $35.1M | Put options by funds: $6.93M

150% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 10

42% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 36

23% more capital invested

Capital invested by funds: $710M → $875M (+$165M)

14% more funds holding

Funds holding: 111 → 126 (+15)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
126
Holders Change
+15
Holders Change %
+13.51%
% of All Funds
3.36%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
25
Increased
51
Reduced
36
Closed
10
Calls
$35.1M
Puts
$6.93M
Net Calls
+$28.1M
Net Calls Change
+$36.4M

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$15.4M
2
SCM
Scopia Capital Management
New York
+$8.4M
3
Millennium Management
Millennium Management
New York
+$7.99M
4
CCM
Consonance Capital Management
New York
+$7.33M
5
KCM
Kingdon Capital Management
New York
+$7.23M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$21.8M
2
Macquarie Group
Macquarie Group
Australia
-$19.8M
3
PA
Perceptive Advisors
New York
-$15.9M
4
PWAM
Park West Asset Management
California
-$14.2M
5
Citadel Advisors
Citadel Advisors
Florida
-$9.78M
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
26
Amici Capital
New York
$7.39M -$5.86M -308,000 -48%
TCM
27
Tekla Capital Management
Massachusetts
$7.38M – – –
Two Sigma Investments
28
Two Sigma Investments
New York
$6.74M +$4.75M +249,657 +484%
Dimensional Fund Advisors
29
Dimensional Fund Advisors
Texas
$6.38M +$4.36M +228,786 +407%
TA
30
Teachers Advisors
New York
$6.2M +$808K +42,430 +18%
Geode Capital Management
31
Geode Capital Management
Massachusetts
$6.17M +$95K +4,989 +2%
GTC
32
Ghost Tree Capital
New York
$5.59M +$4.76M +250,000 New
NI
33
Numeric Investors
Massachusetts
$5.5M +$4.68M +245,800 New
SIM
34
Spark Investment Management
New York
$5.12M -$1.46M -76,600 -25%
BA
35
Boston Advisors
Massachusetts
$4.89M +$3.64M +191,380 +710%
SCA
36
Signpost Capital Advisors
New York
$4.55M +$3.87M +203,141 New
IHM
37
Iguana Healthcare Management
New York
$4.48M +$3.81M +200,000 New
WSA
38
Wall Street Associates
California
$4.45M – – –
SFM
39
Sphera Funds Management
Israel
$4.25M +$761K +40,000 +27%
AL
40
AJO LP
Pennsylvania
$3.75M +$3.19M +167,524 New
GKIM
41
GW&K Investment Management
Massachusetts
$3.6M +$1.23M +64,874 +68%
OAM
42
Oxford Asset Management
United Kingdom
$3.6M -$1.05M -55,409 -26%
Point72 Asset Management
43
Point72 Asset Management
Connecticut
$3.38M -$457K -24,000 -14%
MC
44
Maverick Capital
Texas
$3.33M +$2.83M +148,661 New
BIM
45
BlackRock Investment Management
Delaware
$3.3M -$10.8K -568 -0.4%
Charles Schwab
46
Charles Schwab
California
$2.96M +$213K +11,187 +9%
AQR Capital Management
47
AQR Capital Management
Connecticut
$2.7M +$641K +33,678 +39%
EA
48
Emerald Acquisition
Washington
$2.43M -$422K -22,191 -17%
American Century Companies
49
American Century Companies
Missouri
$2.19M +$1.87M +98,096 New
Two Sigma Advisers
50
Two Sigma Advisers
New York
$1.95M +$744K +39,100 +82%
1
2
3 4 5

TVTX Hedge Fund Activity: Q3 2016 in Review

126 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2016, worth a combined $875M — up 23% from $710M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new TVTX positions and 10 closed out — a net gain of 15 holders — while 51 added to existing stakes and 36 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $15.4M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $21.8M sold.

  • 126 institutional investors held Travere Therapeutics (TVTX) as of Q3 2016, up from 111 in Q2 2016.
  • Funds reported $875M of Travere Therapeutics stock for Q3 2016, up 23% quarter-over-quarter.
  • 25 funds opened new Travere Therapeutics positions in Q3 2016 and 10 closed out, a net change of +15 holders.
  • The largest Travere Therapeutics buyer in Q3 2016 was Broadfin Capital, an estimated $15.4M added.
  • The largest Travere Therapeutics seller in Q3 2016 was EcoR1 Capital, an estimated $21.8M sold.

Based on aggregated 13F filings for Q3 2016.